Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Other financing activities (2024)

Inhibikase Therapeutics (IKT) has disclosed Other financing activities for 1 consecutive years, with -$30608.0 as the latest value for Q1 2024.

  • On a quarterly basis, Other financing activities changed N/A to -$30608.0 in Q1 2024 year-over-year; TTM through Mar 2025 was -$30608.0, a N/A change, with the full-year FY2023 number at -$138556.0, changed N/A from a year prior.
  • Other financing activities was -$30608.0 for Q1 2024 at Inhibikase Therapeutics.
  • In the past five years, Other financing activities ranged from a high of -$30608.0 in Q1 2024 to a low of -$30608.0 in Q1 2024.